The fundamental principles that guide us
How We Do Business
TRANSPARENCY
We want to share what we do
and how we do it
People and their health are at the heart of the work of the pharmaceutical industry. That is why we all need to work together: the health system, with its centres and infrastructures; health professionals, with their knowledge and clinical experience; the pharmaceutical industry, with its competence and financial capacity; and the patients themselves, with their experience in managing disease. It is a proven and successful model, which in recent decades has revolutionized healthcare.
As a result of this collaboration:
-
95%
of available drugs have been developed under this model
-
70%
increase in life expectancy in recent years attributed to new drugs
We invest in research and development, and establish collaborations with organizations and healthcare professionals.
This collaboration must be accompanied by total transparency and a commitment to keeping society informed. The aim is to explain the nature of this work, the added value it represents and what it contributes to society’s well-being.
Collaboration between industry and healthcare professionals is particularly important.
This collaboration is of great benefit to professionals, as it updates and improves their knowledge of medicines, helps them to continue their ongoing training and allows them to participate in cutting-edge research at an international level. All this improves the quality of care in the health system and, therefore, benefits patients, the ultimate reason for healthcare.
As an example of our commitment to transparency and in order to strengthen the trust of society, every year we publish annually the value transfers and payments made to professionals, health organizations and patient associations, as well as the transfers of value related to research and development.
Value transfers
The direct or indirect value transfers shown below reflect: Ferrer's support for healthcare professionals to facilitate their continuing education; fees for the provision of services to healthcare professionals or organisations based on their knowledge and clinical experience; and payments for the participation and contribution of centres and professionals in R&D.
Value transfers related to Research and Development
*In addition, Value Transfers related to R+D were made from the German subsidiary for an amount of 50,000 euros.
** In addition, Value Transfers related to R+D were made from the German subsidiary for an amount of 25,000 euros.
Codes of ethics and product regulations.
Ferrer is a member of various sectoral employers' associations and fully complies with the respective codes of ethics, as well as with all the regulations that apply to our products.
Related news
-
Ferrer included in the ranking of the most ethical companies in the world in 2026
5 -
Ferrer reinforces its impact in 2024 with more social and environmental investment, B Corp leadership and advances in sustainability
5 -
We are the highest scoring pharmaceutical B Corp in the world
5 -
Ferrer is recognized as a leader in compliance with ethical and responsible corporate practices
5 -
Discover our 2023 Sustainability Report
5
